Neoadjuvant Immune Checkpoint Inhibitor Combo Promising for NSCLC

Researchers compared the percentage of  non-viable tumor and tissue resident memory tumor infiltrating lymphocytes for nivolumab plus ipilimumab vs nivolumab alone.

Source: CancerNetwork - June 2, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news